The case against universal WBC reduction (and for the practice of evidence-based medicine)

Transfusion

Volumn 40, Issue 12, 2000, Pages 1522-1527

  Goodnough, Lawrence T ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BACTERIAL INFECTION; BLOOD FILTRATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CANCER RECURRENCE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEVER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; LEUKOCYTE; MAJOR CLINICAL STUDY; NOTE;

BLOOD COMPONENT REMOVAL; EVIDENCE-BASED MEDICINE; HUMANS; LEUKOCYTES;

EID: 0034518124     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40121522.x     Document Type: Note

References (55)

1. Biologic effects of leukocytes present in transfused cellular blood products
2. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse?
3. Multicenter randomized controlled trials in transfusion medicine
4. Deleterious effects of transfusion-associated immunomodulation: Appraisal of the evidence and recommendations for prevention
5. Leukocyte reduction of blood components: Public policy and new technology
6. Further studies of blood infectivity in an experimental model of transmissible sponge for encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans
7. Leukocyte reduction in blood component therapy
8. Guidelines on the clinical use of leucocyte-depleted blood components
9. Febrile transfusion reaction: What blood component should be given next?
10. Febrile reactions after platelet transfusion: The effect of single versus multiple donors
11. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
12. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration
13. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets
14. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets
15. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations
16. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia
17. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization
18. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
19. Prevention of HLA immunization with leukocyte-poor packed RBCs and platelet concentrates obtained by filtration
20. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - A randomized trial
21. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial
22. Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective randomized study
23. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis
24. 9/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
25. A multicenter study of platelet recovery and utilization in patients after myeloblative therapy and hematopoietic stem cell transplantation
26. Improvement of kidney-graft survival with increased numbers of blood transfusions
27. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells
28. Mononuclear-cell immunisation in prevention of recurrent miscarriages: A randomised trial
29. Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials
30. Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet?
31. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analyis of unconfounded studies
32. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery
33. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
34. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
35. Transfusion of RBCs is associated with increased incidence of bacterial infection after colorectal surgery: A prospective study
36. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery
37. Blood transfusions and prognosis in colorectal cancer
38. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery
39. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial
40. Risk stratification using the Society of Thoracic Surgeons Program
41. Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery
42. Adverse ocular reactions following transfusions - United States, 1997-1998
43. American Red Cross suspends use of Hemasure blood filtration to investigate adverse patient reactions
44. Leukocyte depletion of whole blood and RBCs from donors with hemoblobin sickle trait
45. Ineffective prestorage leukoreduction (PSLR) of whole blood (WB) from African-American donors with sickle cell trait (HB AS) versus controls
46. Universal WBC reduction
47. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
48. Safety of filtered leukocyte-reduced blood products for the prevention of transfusion-associated cytomegalovirus infection
49. Prevention of posttransfusion CMV in the era of universal WBC reduction. A consensus statement
50. What is a transfusion medicine specialist?